MEASURING PREFERENCES FOR SCHIZOPHRENIA OUTCOMES

衡量精神分裂症结果的偏好

• 批准号: 2250798
• 负责人: WILLIAM A HARGREAVES
• 金额: $ 11.55万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-05-01 至 1997-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2250798
• 关键词: abnormal involuntary movement; data collection methodology /evaluation; decision making; drug adverse effect; employment /unemployment; family; hallucinations; housing; human population study; human subject; human therapy evaluation; preference; psychiatrist; psychometrics; questionnaires; schizophrenia; sign /symptom; social adjustment; social support network

Determining the effectiveness of schizophrenia treatments requires aggregate measures that reflect the relative importance of schizophrenia's multiple outcome domains. A lack of understanding of the relative importance of various domains prevents meaningful aggregation of outcome measures and limits inferences drawn from treatment research. This study is designed to develop and apply methods for determining the importance of schizophrenia treatment outcomes by adapting preference assessment methods used in general health status research. The first of two study phases is devoted to method development. Four preference assessment methods (category rating, time trade-off, paired comparison and direct importance rating) used successfully in prior health status research will be evaluated in two expert groups, one comprised of clinicians providing schizophrenia treatment and one of persons with schizophrenia. In the second phase, the two preference assessment methods found to be most feasible, valid and reliable in the method development phase will be compared in a randomized, factorial design including 4 stakeholder groups directly and indirectly involved in schizophrenia treatment (persons with schizophrenia, clinicians providing schizophrenia treatment, family members of persons with schizophrenia and members of the general public). This method and group comparison will (1) determine which methods perform comparably across stakeholder groups in terms of feasibility, validity, reliability and efficiency, (2) determine whether stakeholder group membership or other demographic characteristics affect preferences for treatment outcomes, (3) identify methods best suited for use in future studies of schizophrenia treatment outcome, (4) generate preference weights for key outcomes which can be applied retrospectively to existing research findings as well as in future studies where preference assessment is not practical. Study findings will also inform the study of other serious mental disorders and help to resolve prevailing controversies about the importance of method and stakeholder group differences in health status preference assessment.

确定精神分裂症治疗的有效性需要 反映精神分裂症的相对重要性的综合指标 多个结果域。 对相对人缺乏了解 各领域的重要性妨碍了有意义的成果汇总 衡量和限制从治疗研究中得出的推论。本研究 旨在开发和应用确定以下方面重要性的方法： 精神分裂症治疗效果的偏好评估方法 用于一般健康状况研究。 两个研究阶段中的第一阶段致力于方法开发。四 偏好评估方法（类别评级，时间权衡，配对 比较和直接重要性评级）成功用于先前的健康 现状研究将由两个专家组进行评估，其中一个专家组由以下人员组成： 提供精神分裂症治疗的临床医生， 精神分裂症 在第二阶段，发现两种偏好评估方法 在方法开发阶段最可行、有效和可靠的 在包括4个利益相关者组的随机析因设计中进行比较 直接和间接参与精神分裂症治疗的人（ 精神分裂症，提供精神分裂症治疗的临床医生，家庭 精神分裂症患者和公众人士）。 这种方法和组比较将（1）确定哪些方法执行 在可行性，有效性， 可靠性和效率，（2）确定利益相关者群体是否 成员资格或其他人口统计特征会影响对 治疗结果，（3）确定最适合未来使用的方法 精神分裂症治疗结果的研究，（4）产生偏好 关键成果的权重，可追溯适用于现有的 研究结果以及未来的研究中， 是不切实际的。研究结果还将为其他研究提供信息。 严重精神障碍，并帮助解决普遍存在的争议 关于方法和利益相关者群体差异在健康方面的重要性 地位偏好评估。